anti-Her2 antibody-drug conjugates (MedImmune)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-Her2 antibody-drug conjugates (MedImmune)
Drug Alias NameHer2/neu monoclonal antibody-cytotoxic drug conjugate (Allozyne)AZ-05
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAllozyne
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAllozyneMedimmune Llc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A